DMAA Drugs Made In America Acquisition Corp. Ordinary Shares
Financial Services$10.59+0.00%OpenMarket Cap: $357.1M
As of 2026-05-26
Valuation
View DetailsP/E (TTM)
61.55
PEG
—
P/B
1.04
P/S
0.00
EV/EBITDA
-136.01
DCF Value
—
FCF Yield
-0.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
2.9%
ROA
2.8%
ROIC
-1.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $0.00 | $2.0M | $— |
| Q4 null | $0.00 | $213.0K | $— |
| FY null | $0.00 | $5.9M | $— |
| Q3 null | $0.00 | $2.2M | $— |
Trading Activity
Insider Trades
View AllStockwell Lynndirector, 10 percent owner, officer: CEO and Exe. Chair of Board
BuyTue Feb 18
Drugs Made In America Acquisition LLC10 percent owner
BuyTue Feb 18
Stockwell Lynndirector, 10 percent owner, officer: CEO and Executive COB
SellTue Feb 04
Stockwell Lynndirector, 10 percent owner, officer: CEO and Executive COB
SellTue Feb 04
Drugs Made In America Acquisition LLC10 percent owner
SellTue Feb 04
Company Info
Sector
Financial Services
Industry
Shell Companies
Country
US
Exchange
—
Beta
-0.00
Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.